Demographic and Clinical Characteristics of the Severe Covid-19 Infections:

r First Report from Mashhad University of Medical Sciences, Iran

*** Running title:** Characteristics of Covid-19 in Iran

Ladan Goshayeshi^{1,2, †}, Mina Akbari Rad^{3, †}, Robert Bergquist⁴, Abolghasem Allahyari³, members of the MUMS
 Covid-19 Research Team⁵, Benyamin Hoseini^{6,7, *}

٦

Members of the MUMS Covid-19 Research Team: Kamila Hashemzadeh, Nasrin Milani, Mahdi Gholian-Aval, Fariba
 Rezaeitalab, Mohammad Jafar Sadeghi Quchani, Zahra Nahbandani, Zahra Javid, Mahnaz Mozdourian, Mohammad
 Ali Yaghoubi, Zahra Mozaheb, Mohsen Seddigh-Shamsi, Mohammad Moeini Nodeh, Shima Nabavi, Mandana
 Khodashahi, Hooman Mosannen Mozaffari, Mohammadreza Farzanehfar, Zahra Lotfi, Alireza Shariati, Shekoofe
 Bonakdaran, Zahra Rezaieyazdi, Zahra Mirfeizi, Maryam Miri, Reza Bassiri, Sajjad Ataei Azimi

۱۲ ۱۳

¹Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences,
 Mashhad, Iran.

- ¹⁷ ²Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- ¹ ³ *Department of internal medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 1A ⁴Ingerod, SE-454 94 Brastad, Sweden; Formerly UNICEF/UNDP/World Bank/WHO Special Programme for
- 19 Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.
- Y. ⁵A full list of the research team members is provided in Supplementary Note online.
- ⁶Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- ⁷⁷Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran.
- ۲۳
- ⁷£ [†]Ladan Goshayeshi and Mina Akbari Rad contributed equally as joint lead authors.
- ۲٥
- ۲٦
- *Corresponding author: Benyamin Hoseini, Pharmaceutical Research Center, Mashhad University of Medical
- Sciences, Mashhad, Iran; Department of Health Information Technology, Neyshabur University of Medical Sciences,
- Neyshabur, Iran; Tel: +985143306219, Cellphone: +989127858864; Email: Hoseinib1@nums.ac.ir.
- ۳.
- ۳١
- ٣٢
- ٣٣

٣٤ Abstract

۳0 Background. Coronavirus Disease 2019 (Covid-19) is expanding worldwide. The characteristics of this infection in ٣٦ patients varies from country to country. To move forward, clinical data on infected patients are needed. Here, we ۳۷ report a comparison between fatalities and recovery of patients with severe Covid-19, based on demographic and ۳۸ clinical characteristics.

۳۹ Methods. Between 5 March and 12 May 2020 in Mashhad, Iran, 1,278 of 4,000 suspected Covid-19 patients were ٤٠ confirmed positive by real-time reverse-transcriptase-polymerase-chain-reaction assay of upper respiratory ٤١ specimens. We compared the demographic, exposure history and clinical symptoms of 925 survivors and 353 fatal ٤٢ cases with confirmed disease.

٤٣ Results. Mean (SD) age for all confirmed patients was 56.9 (18.7) years, 67.1 (15.9) years in fatal cases and 53.0 ٤٤ (18.3) years in survivors. Multivariable logistic regression analysis showed that the outcome of patients was associated 20 with age (OR = 1.049, P = 0.0001, 95% CI = 1.040-1.057). Despite a high burden of Covid-19 infections in the 30-٤٦ 39 and 40-49 year age groups, most of these (89.6% and 87.2%, respectively) recovered. The median (IQR) duration ٤٧ of hospitalization was 9.0 (6.0-14.0) days. The most prevalent co-morbidities were cardiovascular disorders (21%) ٤٨ and diabetes (16.3%). Dyspnoea (72.7%), cough (68.1%) and fever (63.8%) were the most frequent clinical symptoms. ٤٩ Healthcare workers, of whom two (3%) died, comprised 5.2% of infected-cases. Combination antiviral and antibiotic ο. therapy was used in 43.0% of cases.

01 Conclusions. The characteristics of severe Covid-19 varied substantially between fatal cases and survivors, with ٥٢ diabetes and cardiovascular disorders the most prevalent co-morbidities. In contrast to other studies, there were a ٥٣ higher number of fatalities in younger patients in our settings.

- 0 2
- 00

Keywords. COVID-19, SARS-COV-2; Epidemiological characteristics; symptoms, Iran

٥٦

- ٥٧
- ٥٨

۹ Background

٦. In late 2019, the city of Wuhan, Hubei Province, China became the centre of an unusual pneumonia-like disease of an ٦١ unknown cause [1-4]. In December 2019, Chinese scientists realized that this condition was caused by a novel ٦٢ Coronavirus, first called 2019-nCOV [5, 6]. On January 7, 2020, scientists isolated this novel type of Coronavirus ٦٣ from the sputum of these patients, which was on February 11, 2020 classified as Severe Acute Respiratory Syndrome ٦٤ Coronavirus type two (SARS-CoV-2) by the International Committee on Taxonomy of Viruses [6, 7]. On the same ٦0 date, the World Health Organization (WHO) named the disease caused by this virus coronavirus disease 2019 (Covid-٦٦ 19) in the International Classification of Diseases [6]. As of March 11, 2020 when the Covid-19 outbreak had spread ٦٧ worldwide and reached 118,319 confirmed cases and 4,292 confirmed deaths, WHO declared it a global pandemic [8-٦٨ 10]. The initial source of Covid-19 is still unknown, but it is now confirmed that the first known case of this disease ٦٩ was linked to the Huanan seafood market of Wuhan City, which was closed on January 1, 2020 to control the situation ٧. [4, 11].

SARS-CoV-2 is a member of the Coronaviridae family that consists of a single-stranded positive-sense RNA [4]. So
 far, two human infections by viruses related to Coronaviridae family are known: the Severe Acute Respiratory
 Syndrome (SARS), caused by SARS-CoV, which emerged in China in 2002 and spread across 37 countries, and the
 Middle-East Respiratory Syndrome (MERS), caused by MERS-CoV, which was first seen in Saudi Arabia in 2012
 [4]. There were two separate outbreaks of SARS in the period 2002-2004, while cases of MERS still occur though
 only rarely [12]. SARS-COV-2 is genetically related to SARS-CoV with both of them being beta-coronaviruses [13,
 14].

The clinical manifestation of Covid-19 varies from asymptomatic infection to severe viral pneumonia with multisystem failure leading to death [3, 15, 16]. The most common clinical manifestations include, but are not limited to, fever, non-productive cough, myalgia, fatigue and dyspnoea. Chest radiography shows bilateral lung infiltrations indicative of pneumonia and laboratory indices include increased erythrocyte sedimentation rate and C-Reactive protein and, lymphopenia [15, 17]. In severe cases, acute respiratory distress syndrome, acute cardiac and kidney injury and shock can occur, which may lead to irreversible organ failure and death [17].

At By May 16, 2020, there were 4,602,900 confirmed cases with 307,135 confirmed deaths globally, translating into a case fatality rate (CFR) of 6.67%. At this date, there were 116,635 confirmed cases with 6,902 deaths in Iran resulting

in the same CFR (<u>WHO</u> daily report). We aimed to describe the characteristics of patients with Covid-19 in Razavi
 Khorasan, a province in Iran which has a population of 6.5 million. Herein, we report demographic and clinical
 characteristics of patients with severe Covid-19 in Mashhad, the second largest city in Iran and capital of Razavi
 Khorasan.

۹.

91 Materials and methods:

٩٢ We undertook a retrospective cross-sectional study of consecutive Covid-19 patients diagnosed between 5 March and ٩٣ 12 May 2020 in Mashhad, Iran. Data were collated by the centre for Diseases Prevention and Control of Mashhad ٩٤ University of Medical Sciences. Severe illness usually begins approximately 1 week after the onset of symptoms. 90 Dyspnea is the most common symptom of severe disease and is often accompanied by hypoxemia [6, 17]. Patients ٩٦ with severe Covid-19 should be hospitalized for careful monitoring. In our study all cases were symptomatic and 94% ٩٧ of the cases were inpatients from hospitals affiliated to Mashhad University of Medical Sciences. Thus, we called ٩٨ these cases in this study as sever Covid-19. Among 4,000 mostly severe cases suspected to be infected that had 99 undergone further investigation, 1,278 (32.0%) were confirmed as true Covid-19 cases by real-time reverse-1... transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and/or pharyngeal swabs. Clinical and 1.1 demographic results of laboratory-confirmed cases were included in a review of exposure history, health outcomes 1.1 and symptoms. Admission to an intensive care unit (ICU) or the use of mechanical ventilation within this cohort with 1.7 severe symptoms were the primary end-points of the study. Secondary end-point included duration of hospitalization, 1.2 history of infection (defined as the time from onset of symptom(s) until discharge from the hospital or death), and 1.0 outcome (dead or recovered). Fever was defined as axillary temperature >37.5°C. Prescribed medications included 1.7 lopinavir/ritonavir, antibiotics, and oseltamivir.

N•V Statistics Analysis

1.A Categorical variables were summarized as frequencies and percentages. The Shapiro–Wilk test was used to evaluate normality of data. Normally distributed data were expressed as mean ± standard deviation (SD), and skewed data as median and interquartile range (IQR). Two-tailed Student's t and Mann–Whitney U tests were used to compare grouped continuous variable data where appropriate. Chi-square and Fisher's exact tests were used to perform

- intergroup and categorical comparisons as appropriate. Logistic regression was performed to multivariable analysis,
- comparing deceased and recovered patients. Reported p-values of <0.05 were considered statistically significant. SPSS
- software, version 16 (SPSS Inc., Chicago, IL, USA) was used to analyse the data.
- **Results:**
- Demographic characteristics. Of the 1,278 confirmed Covid-19 patients, 353 (27.6%) died and 925 recovered. Mean (SD) age for confirmed patients was 56.9 (18.7) years, for deceased cases 67.1 (15.9) years and for recovered cases 53.0 (18.3) years. There was a statistically significant association between age and mortality with the mortality 17. rate rising with age (Table 1). Multivariable logistic regression analysis also showed that the outcome of patients was associated with age (OR = 1.049, P = 0.0001, 95% CI = 1.040 - 1.057), when adjusted for gender, therapeutic approach, body temperature, and duration of hospitalization. Considering age as categorical variable (≤50 vs. >50 years), multivariable logistic regression revealed that odds of death among patients >50 years was more than that among those \leq 50 years (OR = 4.7, P = 0.0001, 95% CI = 3.4–6.5). Despite the high frequency of Covid-19 infections accrued in the 30-39 and 40-49 age groups, most of them (130/145 = 89.6 and 170/195 = 87.2%, respectively) recovered (Table 1; Fig. 1). Twenty-six (2.0 %) of all 1.278 confirmed cases were <20 years old, and 28 (2.2%) were >89 years (Fig. 1). Most (793/1,278 = 62%) of the confirmed patients were males, however there was no statistically significant difference in outcomes with reference to gender (Table 1). ۱۳. 12.

Variable investigated		Outcome Number (%)		P-value
		Deceased	Recovered	
		(n = 353)	(n = 925)	
Continuous age - mean (SD)	67.1 (15.9)	53.0 (18.3)	0.0001
Age (categorical)	0-9	1 (0.3)	12 (1.3)	
	10-19	1 (0.3)	12 (1.3)	_
	20-29	4 (1.1)	66 (7.1)	_
	30-39	15 (4.2)	130 (14.1)	_
	40-49	25 (7.1)	170 (18.4)	_
	50-59	47 (13.3)	193 (20.9)	0.0001
	60-69	104 (29.5)	165 (17.8)	_
	70-79	74 (21.0)	102 (11.0)	
	80-89	62 (17.6)	67 (7.2)	
	90-99	19 (5.4)	8 (0.9)	
	100-109	1 (0.3)	0 (0.0)	
Gender	Female	129 (36.5)	356 (38.5)	0.50
	Male	224 (63.5)	569 (61.5)	0.52
Therapeutic approach	Antiviral & antibiotic	149 (42.2)	401 (43.4)	
	Conservative	71 (20.1)	139 (15.0)	0.08
	Antiviral	133 (37.7)	385 (41.6)	
Specific medication	Lopinavir/ritonavir and	131 (37.1)	120 (13.0)	
used	antibiotic ^a			NA
	Oseltamivir ^b	222 (62.9)	805 (87.0)	
Body temperature (C°) - mean (SD)		37.6 (0.76)	37.7 (0.73)	0.09
Hospitalization (days) -	median (IQR)	9.0 (6.0-14.0)	9.0 (6.0-14.0)	0.18

Table 1. Association between Covid-19 status and outcomes

10.

^aprescribed for severe cases; ^bprescribed for mild cases; NA= Not applicable.

101 107

12A 129



frequent clinical symptoms (Table 2). Overall, 1,251/1,278 (97.9%) of the cases had at least one clinical symptom.

- Compared with survivors, deceased cases showed a higher rate of co-morbidities including cardiovascular disorders
- (28.3% vs. 18.2%), diabetes (22.9% vs. 13.7%) and chronic respiratory disorders (8.2% vs. 3.0%) (Table 2).
- 177
- ١٦٨

Frequency	Frequency (%)					
	Among all	Among	Among			
	infected cases	deceased cases	recovered cases			
Co-morbidity	(n=1,278)	(n= 353)	(n= 925)			
Cardiovascular disorder	268 (21.0)	100 (28.3)	168 (18.2)			
Diabetes	208 (16.3)	81 (22.9)	127 (13.7)			
Liver disorders	45 (3.5)	18 (5.1)	27 (2.9)			
Kidney disorders	40 (3.1)	19 (5.4)	21 (2.3)			
Chronic resp. disorder	57 (4.5)	29 (8.2)	28 (3.0)			
Acute resp. distress syndrome (ARDS)	13 (1.02)	4 (1.1)	9 (0.1)			
Mild pneumonia	136 (10.64)	24 (6.8)	112 (12.1)			
Symptom						
Fever	815 (63.8)	244 (69.1)	571 (61.7)			
Cough	870 (68.1)	229 (64.9)	641 (69.3)			
Dyspnoea	929 (72.7)	287 (81.3)	642 (69.4)			
General malaise	247 (19.3)	61 (17.3)	186 (20.1)			
Myalgia	199 (15.6)	49 (13.9)	150 (16.2)			
Confusion	87 (6.8)	41 (11.6)	46 (5.0)			
Sore throat	152 (11.9)	31 (8.8)	121 (13.0)			
Diarrhoea	47 (3.7)	11 (3.1)	36 (3.9)			
Nausea & vomiting	113 (8.8)	27 (7.6)	86 (9.3)			
Headache	114 (8.1)	24 (6.8)	90 (9.7)			
End-points						
ICU admission	151 (11.8)	70 (19.8)	81 (8.7)			
Using mechanical ventilation	499 (39.0)	176 (49.8)	323 (34.9)			
Other						
Exposure or visit to hospital within the	131 (10.2)	38 (10.7)	93 (10.0)			
last 14 days						
Contact with a respiratory patients in the	616 (48.2)	126 (35.7)	490 (53.0)			
last 14 days						

179

۱۷۰

Therapeutic approach

Most patients (550/1,278; 43%) received antiviral and antibiotic combination therapy, 518/1,278 (40.5%) received
 antiviral therapies only, and 210/1,278 (16.5%) did not receive antiviral or antibiotic therapy. No significant
 differences in the treatment approach between patients that died and those that recovered were observed (Table 1).
 Mortality rates associated with lopinavir/ritonavir and antibiotic combination therapy and oseltamivir therapy were
 37.1% and 62.9%, respectively (Table 1).

177

Of the 1,278 confirmed cases, 67 (5.2%) were healthcare workers, of whom 2 (3.0%) died. Thirty-one (46.3%) of these healthcare workers were presumed to have been infected through occupational exposure to infected patients. Cough (77.6%), fever (68.7) and dyspnoea (56.7%) were the commonest symptoms in healthcare workers with Covid-19. Six (9.0%) had comorbidities (cardiovascular disorders, n=3; diabetes, n=3). Seven (10.4%) of the healthcare workers required mechanical ventilation and 6 were admitted to ICU.

۱۸۳

۱۸٤ Discussion

This is the first study from Mashhad, Iran, to report the characteristics of patients with severe confirmed Covid-19. Increasing age was associated with an increased risk of mortality. The most frequent co-morbidities were cardiovascular disorders and diabetes, and the most frequent symptoms were dyspnoea, cough, and fever. The highest burden of disease clustered in the 50-59 and 60-69 year age groups, while the highest CFR was patients aged 80-89 years. These findings are in line with previous reports [6, 18].

19.

191 Mean (SD) age of Iranian Covid-19 patients in our study was 56.9 (18.7) years, which is similar to other studies [17, 198 19, 20], but older than that reported by Guan et al. [2] in china who reported a median age (IQR) of 47.0 (35.0 - 58.0) ۱۹۳ years, with 55.1% of their cases were between 15-49 years, and younger than the median of 64 years reported in other 192 studies [4, 21]. Although, the most frequent Covid-19 infection occurred in the 50-59 and 60-69 age groups in our 190 study, the frequency of infection was also considerable in the 30-39 and 40-49 year age groups. The high frequency 197 of Covid-19 infection in these age groups may be due to the low median age (30 years) of the Iranian population ۱۹۷ and/or due to inclusion of mainly working-age population in this age group [22]. It seems that the frequency of Covid-۱۹۸ 19 infections rises considerably from age group of 50-59 years [23, 24]. In contrast to findings in China and Italy [6, 199 25], we found a considerably higher proportion of fatalities in the age groups panning the range from 20-50 years. ۲.. This high proportion of fatalities in young people may be due to differences in life expectancy of different countries ۲.۱ [26]. For lower- and middle-income countries, the proportion of deaths among younger age groups appears ۲.۲ substantially larger. Another reason for this high proportion of fatalities in young people may be due to unknown co-۲.۳ morbidities of these people. Elderly people with known co-morbidities may take more care of themselves than young Y• ź people with unknown co-morbidities. Also, it may be due to shortage of ICU that caused some patients were
 Y• o mechanically ventilated in ordinary wards, i.e. outside ICU.

۲.٦

 $\Upsilon \cdot \Upsilon$ In our study, the prevalence of the Covid-19 infection was higher among men (62%) compared with the reports of $\Upsilon \cdot \Lambda$ China (49.3% - 54.3%) [17, 21]. However, our finding of male predominance in severe cases was similar to reports $\Upsilon \cdot \P$ from Italy (60%) [27], and the United States (63%) [4].

۲١.

117 Huang et al [18] reported a CFR of 15% among hospitalized Covid-19 cases in China. According to the WHO daily 212 report, the crude CFR was 5.6% in China by May 10, 2020. At the beginning of the Covid-19 outbreak in Italy, the 212 crude CFR was 11.8% (12,430/105,792) [28], but this decreased as the number of cases increased. In our study, RT-212 PCR testing was only used for symptomatic cases, including more severely ill patients at a high risk of mortality. This 210 selection bias, and the fact that our study describes outcomes in confirmed cases during a comparatively short window 212 of time, limits our ability to arrive at accurate estimates of CFR relating Covid-19 in our setting. Long-term screening ۲۱۷ of all population at risk should facilitate reporting of more reliable CFR estimates in future studies. Estimation of the ۲۱۸ infection fatality rate (IFR) would also be of interest, but would require reliable antibody detection assay and large 219 population-based samples.

۲۲.

According to WHO interim clinical guidance (Rev. March 20, 2020) [29], fever, caught, fatigue and anorexia are the most common signs of Covid-19 and our findings comply with this. However, in our study dyspnoea (72.7%) was twice as prevalent compared to WHO estimates (31-40%) [29]. Prevalence of dyspnoea in our study, was similar to that from United States, however [4, 30]. The prevalence of dyspnoea in China complies with the WHO guidelines [19, 21, 31], although they may also be slightly higher [32]. The WHO should update the information on symptoms and signs of Covid-19 based on new global data, pointing out that there may be differences with respect to region.

۲۲۷

Cardiovascular disorders (21%) and diabetes (16.3%) were the most prevalent co-morbidities among Covid-19
patients in our study. Previous studies have reported diverse prevalence rates for cardiovascular disorders (11-45%)
and diabetes (13-35%) [4, 19, 30, 33]. Meta-analyses report pooled prevalence of 8.4% and 12% for cardiovascular

disorders, and 8.0% to 9.7% for diabetes [34, 35]. Assessing the association between patients' awareness of Covid-19and risk factors for severe disease and adherence to prevention protocols should be evaluated in future studies.

۲۳۳

The fatality rate among healthcare workers was 3% in our study, considerably higher than that reported in China
(0.33%) [36]. This may be due to a shortage of personal protective equipment (PPE) at the early stages of the Covid19 pandemic in Iran. Future studies should focus on the impact that availability of PPE had on CFR among healthcare
workers in Iran, and other countries.

۲۳۸

Huang et al [37] reported that 32% of patients were admitted to ICU, whereas in our study only 11.8% received ICU
care. The fatality rate among patients treated in ICU was 46.3% in our study, lower than that (78%) reported by Zhou
et al. [6]. All patients admitted to ICU received broad-spectrum antibiotics and antiviral medications, a combination
that may have contributed to the lower mortality rate in our setting. Importantly, the use if the RT-PCR testing of all
ICU-admitted patients strengthened the reliability of CFR estimates of this category of patients.

٢ ٤ ٤

Yio To our knowledge, this is the first study to address the characteristics of Covid-19 patients confirmed by RT-PCR in Mashhad, Iran. However, it has limitations, chiefly in that the RT-PCR testing approach focused on cases with severe symptoms, most of which were hospitalized. We analysed data from patients treated in facilities served by the Mashhad University of Medical Sciences, and so did not cover all areas of Razavi Khorasan, although most patients requiring hospitalization are routinely referred to this city. Despite the above-mentioned limitations, we feel that our findings are instructive and will inform future research, both in Iran and internationally.

101

In summary, the frequency of Covid-19 fatalities rose considerably from 30-39 years, with a higher number of fatalities
 in younger patients than in international studies. Fever, cough, and dyspnoea were common symptoms among
 hospitalized patients with Covid-19. Diabetes and cardiovascular disorders were the most prevalent co-morbidities,
 as observed in other studies.

202

$\gamma \circ \gamma$ List of abbreviations:

YoA Covid-19: Coronavirus Disease 2019

- SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- SARS: severe acute respiratory syndrome
- ICU: intensive care unit
- RT-PCR: real-time reverse-transcriptase polymerase chain reaction
- ۲٦٣

۲٦٤ Declarations

- *Ethics approval.* This study was approved by the Ethics Committee of the Mashhad University of Medical Science
- (Ethics code: IR.MUMS.REC.1398.308).
- Consent for publication. Not applicable.
- Availability of data and materials. The datasets used and/or analysed during the current study are available from the
- corresponding author on reasonable request.
- YV. *Competing interests.* The authors declare that they have no competing interests.
- *Funding*. This work was supported by Mashhad University of Medical Sciences (grant number of 981800).
- Authors' contributions. BH, RB designed the study design. All authors contributed in data gathering and
- interpretation of the results. LG, MAR, BH wrote the first draft of the manuscript. RB edited final version of the
- manuscript. All authors read, commented and approved the final manuscript.
- Acknowledgment. We would like to thank all personnel of Mashhad University of Medical Sciences for their
- ۲۷۶ supports.
- ۲۷۷

۲۷۸ **References**

Munster VJ, Koopmans M, van Doremalen N, et al. A Novel Coronavirus Emerging in China - Key Questions
 for Impact Assessment. The New England journal of medicine. 2020. doi: 10.1056/NEJMp2000929. PubMed PMID:
 31978293.

YAY2.Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New EnglandYAYJournal of Medicine. 2020.

YAE
 Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England
 YAO
 Journal of Medicine. 2020. doi: 10.1056/NEJMoa2002032.

YAN 4. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically III Patients in the Seattle Region - Case
 YAN Series. The New England journal of medicine. 2020. doi: 10.1056/NEJMoa2004500.

- YAA 5. Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus. Clinical Infectious
 YAA Diseases. 2020. doi: <u>https://doi.org/10.1093/cid/ciaa112</u>.
- 71. 6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/s0140-6736(20)30566-3. PubMed PMID: 32171076.
- 7. Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet. 2020;0(0). doi: 10.1016/S0140-6736(20)30607-3.
- Kelvin DJ, Rubino S. Fear of the novel coronavirus. The Journal of Infection in Developing Countries.
 2020;14(01):1-2.
- Y٩A
 9. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020,
 Y٩٩
 Vol 12, Page 372. 2020;12(4):372-. doi: 10.3390/V12040372.
- McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King
 County, Washington. New England Journal of Medicine. 2020:NEJMoa2005412-NEJMoa. doi:
 10.1056/NEJMoa2005412.
- r. r11.Mahase E. China coronavirus: what do we know so far? BMJ (Clinical research ed). 2020;368:m308. doi:r. t10.1136/bmj.m308.
- r_{12} de la Cueva-Alique I, Munoz-Moreno L, de la Torre-Rubio E, et al. Water soluble, optically active monofunctional Pd(ii) and Pt(ii) compounds: promising adhesive and antimigratory effects on human prostate PC-3
- cancer cells. Dalton transactions (Cambridge, England : 2003). 2019;48(38):14279-93. Epub 2019/09/05. doi: 10.1039/c9dt02873k. PubMed PMID: 31482936.
- T. 9
 13. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected
 The Patients. New England Journal of Medicine. 2020. doi: 10.1056/NEJMc2001737.
- T1114.Liangsheng Zhang F-mSFCZL. Origin and evolution of the 2019 novel coronavirus Supplementary data.T11Clinical Infectious Diseases. 2020. doi: https://doi.org/10.1093/cid/ciaa112.
- The second sec
- **16.**Goshayeshi L, Milani N, Bergqueist R, et al. Covid-19 infection without respiratory symptoms: case report**17.1**of diagnosing a 14 year-old patient with acute abdomen. 2020.
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
 Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020:10.1001/jama.2020.1585. doi:
 10.1001/jama.2020.1585. PubMed PMID: 32031570.
- TY18.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,TY1China. The Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
- Chen K, Liao QL, Ma ZW, et al. Association of soil arsenic and nickel exposure with cancer mortality rates, a town-scale ecological study in Suzhou, China. Environmental science and pollution research international.
 2015;22(7):5395-404. Epub 2014/11/21. doi: 10.1007/s11356-014-3790-y. PubMed PMID: 25410308.
- 20. Long B, Brady WJ, Koyfman A, et al. Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine. 2020.
- Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020. doi: 10.1001/jamacardio.2020.0950.
- Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of Underlying Diseases in Hospitalized Patients with
 COVID-19: a Systematic Review and Meta-Analysis. Archives of Academic Emergency Medicine. 2020;8(1).
- rr123.Bergquist R, Rinaldi L. Covid-19: Pandemonium in our time. Geospatial health. 2020;15(1). Epubrrr12020/04/03. doi: 10.4081/gh.2020.880. PubMed PMID: 32238978.
- 24. Bergquist R SS. COVID-19: end of the beginning? . Geospat health 2020;In press.
- Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
- 26. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-
- elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters.
 Environmental research. 2020;188:109890. Epub 2020/08/28. doi: 10.1016/j.envres.2020.109890. PubMed PMID:
 32846654; PubMed Central PMCID: PMCPMC7327471.
- 7⁴. 27. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected
 With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020. Epub 2020/04/07. doi:
- ۳٤٢ 10.1001/jama.2020.5394. PubMed PMID: 32250385; PubMed Central PMCID: PMCPMC7136855.

- 322 Lippi G, Mattiuzzi C, Sanchis-Gomar F, et al. Clinical and demographic characteristics of patients dying 28. 325 from COVID-19 in Italy versus China. Journal of medical virology. 2020. Epub 2020/04/11. doi: 10.1002/jmv.25860. ٣٤0 PubMed PMID: 32275075.
- 321 29. WHO. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease
- ٣٤٧ (COVID-19) 2020 [cited 2020 March 20]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-٣٤٨ guidance-management-patients.html.
- 729 Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically III Patients With COVID-19 30. 50. in Washington State. JAMA. 2020. doi: 10.1001/jama.2020.4326.
- 501 Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-31. 502 2. European journal of nuclear medicine and molecular imaging. 2020;47(5):1275-80. Epub 2020/02/29. doi: 505 10.1007/s00259-020-04735-9. PubMed PMID: 32107577; PubMed Central PMCID: PMCPMC7080117.
- 302 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 32. 500 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 307 2020. doi: https://doi.org/10.1016/S2213-2600(20)30079-5.
- 301 Xiao K, Zhai J, Feng Y, et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan 33. ۳0Л pangolins. BioRxiv. 2020.
- 809 34. Emami A, Javanmardi F, Pirbonyeh N, et al. Prevalence of Underlying Diseases in Hospitalized Patients with 31. COVID-19: a Systematic Review and Meta-Analysis. Archives of academic emergency medicine. 2020;8(1):e35.
- 311 Epub 2020/04/02. PubMed PMID: 32232218; PubMed Central PMCID: PMCPMC7096724.
- 377 35. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) 377 infection: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official 372 publication of the International Society for Infectious Diseases. 2020. Epub 2020/03/17. doi: 370 10.1016/j.ijid.2020.03.017. PubMed PMID: 32173574.
- 377 Xiang YT, Jin Y, Wang Y, et al. Tribute to health workers in China: A group of respectable population during 36. 311 the outbreak of the COVID-19. International journal of biological sciences. 2020;16(10):1739-40. Epub 2020/04/01. 377 doi: 10.7150/ijbs.45135. PubMed PMID: 32226292; PubMed Central PMCID: PMCPMC7098026.
- 379 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 37.
- ۳۷.
- China. Lancet. 2020;395(10223):497-506. Epub 2020/01/28. doi: 10.1016/s0140-6736(20)30183-5. PubMed PMID: 371 31986264.

3777